PDSB PDSB
Company Profile ↓Company Overview
PDSB (PDSB) is a publicly traded company listed on with a market capitalization of $40.06M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -35.12% |
| 6 Months: | -5.01% |
| 3 Months: | -31.44% |
| 1 Month: | -12.97% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross1d ago
- RSI (14)43.25 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 49.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.11M | 7.62M | 8.14M | 6.67M | 6.52M |
| Operating Income | -8.48M | -8.87M | -9.03M | -9.26M | -10.28M | -10.94M | -11.79M | -13.15M | -10.90M | -16.12M | -736.94K | -567.03K | -710.27K | -4.94M | -4.27M | -5.85M | -4.03M | -2.94M | -3.91M | -3.05M | -5.11M | -6.96M | - | -8.48M | -7.09M | -7.28M | - | -9.42M | -12.70M | -10.52M | - | -10.10M | -8.68M | -10.18M | - | -9.11M | -7.62M | -8.14M | -6.67M | -6.52M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.72M | -7.28M | -7.85M | -6.44M | -6.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 930.88K | 2.14M | 1.15M | 1.11M | 1.01M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.66M | -9.43M | -9.01M | -7.56M | -7.35M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.17M | 0 | 0 | 0 | 0 |
| Net Income | -10.13M | -7.96M | -9.17M | -9.38M | -10.76M | -9.52M | -12.17M | -13.50M | -11.28M | -13.90M | -737.89K | -567.83K | -711.21K | 6.82M | -3.89M | -5.75M | -3.99M | -2.93M | -3.91M | -3.05M | -588.93K | -6.96M | -6.32M | -8.47M | -5.82M | -7.42M | -19.14M | -9.66M | -11.53M | -10.85M | -10.90M | -10.60M | -8.33M | -10.73M | -7.95M | -8.49M | -9.43M | -9.01M | -7.56M | -7.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.39 | -0.19 | -0.21 | -0.14 | -0.03 | -0.24 | - | -0.32 | -0.20 | -0.26 | - | -0.32 | -0.37 | -0.35 | - | -0.30 | -0.23 | -0.29 | - | -0.21 | -0.21 | -0.19 | - | -0.13 |
| R&D Expense | 6.51M | - | 5.35M | 5.98M | 6.72M | - | 7.59M | 8.98M | 6.91M | - | 201.14K | 168.61K | 194.07K | 1.03M | 1.89M | 1.83M | 1.97M | 1.41M | 2.06M | 1.41M | 2.76M | 3.69M | - | 5.16M | 3.76M | 4.35M | - | 5.84M | 8.00M | 6.45M | - | 6.70M | 4.53M | 6.80M | - | 5.83M | 4.21M | 4.58M | - | 3.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 41.67M | 43.05M | 36.32M | 31.54M |
| Operating Income | -6.49M | -13.19M | -26.50M | -39.51M | -51.97M | -3.65M | -21.03M | -14.90M | -21.44M | -41.67M | -43.05M | -36.32M | -31.54M |
| EBITDA | - | - | - | - | - | - | - | - | - | -40.74M | -40.12M | -33.79M | -30.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.32M | 4.21M | 4.67M | 5.34M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -42.05M | -44.35M | -38.48M | -35.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -1.20M | -1.41M | -869.17K | -1.17M |
| Net Income | -6.88M | -12.20M | -28.08M | -38.82M | -50.86M | -3.84M | -7.00M | -14.85M | -16.92M | -40.85M | -42.94M | -37.61M | -34.50M |
| Diluted EPS | - | - | - | - | - | - | - | -0.89 | -0.66 | -1.43 | -1.39 | -1.03 | -0.74 |
| R&D Expense | 4.48M | 8.47M | 17.84M | 24.83M | 34.31M | 830.74K | 6.10M | 7.92M | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 16.85M | 134.09M | 110.91M | 92.62M | 164.43K | 14.49M | 30.89M | - | - | - | - | - | - | - | 77.01M | - | - | - | 59.39M | - | - | - | 45.36M | - | - | - | 30.49M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.48M | - | - | - | 59.06M | - | - | - | 45.05M | - | - | - | 28.25M |
| Cash & Equivalents | 140.93K | - | 7.86M | 13.73M | 130.19M | 106.40M | 88.07M | 103.69K | 12.16M | 28.84M | - | - | - | - | - | - | - | 73.82M | - | - | - | 56.56M | - | - | - | 41.69M | - | - | - | 26.71M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | 2.23M | 2.79M | 3.76M | - | - | - | - | - | - | - | 33.01M | - | - | - | 33.26M | - | - | - | 26.35M | - | - | - | 21.24M |
| Current Liabilities | - | - | - | 3.89M | 8.59M | 6.68M | 12.87M | 1.91M | 2.79M | 3.27M | - | - | - | - | - | - | - | 9.82M | - | - | - | 13.63M | - | - | - | 17.09M | - | - | - | 9.48M |
| Long Term Debt | - | - | - | - | 5.47M | - | - | - | - | - | - | - | - | - | - | - | - | 23.02M | - | - | - | 19.51M | - | - | - | 9.20M | - | - | - | 11.73M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.47M | - | - | - | 23.85M | - | - | - | 21.83M | - | - | - | 16.93M |
| Total Equity | - | -7.65M | -15.35M | -27.83M | 122.48M | 89.28M | -609.53K | -2.07M | 11.70M | 27.13M | 24.37M | 72.99M | 67.86M | - | 55.87M | 51.43M | 47.06M | 44.00M | 41.01M | 32.44M | 24.48M | 26.13M | 37.18M | 30.92M | 22.00M | 19.00M | 22.36M | 15.96M | 9.45M | 9.25M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.17M | - | - | - | 33.09M | - | - | - | 37.99M | - | - | - | 54.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -21.75M | -32.19M | -40.70M | -1.57M | -18.07M | -13.15M | - | -25.71M | -33.64M | -35.03M | -27.75M |
| Investing Cash Flow | - | - | -1.31M | -686.71K | -188.72K | 0 | 29.38M | 0 | - | - | 0 | -29.00K | 0 |
| Financing Cash Flow | - | - | 139.52M | 9.08M | 22.55M | 1.50M | 750.00K | 29.83M | - | 34.29M | 16.38M | 20.19M | 12.77M |
| Capital Expenditure | -136.89K | -884.79K | -1.31M | -686.71K | -188.72K | -0 | - | - | - | - | - | -29.00K | - |
| Free Cash Flow | - | - | -23.06M | -32.88M | -40.89M | -1.57M | - | - | - | -25.71M | -33.64M | -35.06M | -27.75M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 8.58M | -17.26M | -14.87M | -14.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 44.8% | 43.8% | -22.9% | -43.5% | 8,344.1% | 185.7% | -59.8% | -54.7% | - | -92.8% | -164.3% | -197.9% | -372.9% |
| ROCE % | - | -101.9% | -21.1% | -37.9% | -65.2% | 209.0% | -179.8% | -54.0% | - | -62.0% | -94.1% | -128.5% | -150.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PDSB
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher
PDS Biotechnology (PDSB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising ear…
PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...
PDS Biotechnology Corp (PDSB) progresses in clinical trials and patent protection, but faces financial hurdles and competitive pressures.
PDS Biotechnology Q1 Earnings Call Highlights
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first qua…
PDS Biotechnology Corporation Q1 2026 Earnings Call Summary
Moby summary of PDS Biotechnology Corporation's Q1 2026 earnings call
PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcript…
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the im…
PDSB — Frequently Asked Questions
What is the current share price of PDSB?
As of 2026-08-05 17:25 PDT, PDSB trades at $0.73 on NASDAQ/NYSE. Its 52-week range is $0.54 to $1.43.
What is the market capitalisation of PDSB?
PDSB has a market capitalisation of $40.06M on NASDAQ/NYSE.
What is the P/E ratio of PDSB?
PDSB trades at a trailing price-to-earnings (P/E) ratio of -0.99. Its price-to-book (P/B) ratio is 4.33.
Is PDSB a good stock to buy?
This page provides a data-driven analysis of PDSB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.